Clinical trial
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
NCT00376532 · Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00376532 |
|---|---|
| Title | Extracellular Matrix Marker of Arrhythmia Risk (EMMA) |
| Official title | Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices. |
| Acronym | EMMA |
| Lead sponsor | Thomas Jefferson University, Other |
| Collaborators | Medtronic Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac |
| Enrollment | 63 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 15, 2006 |
| Last update posted | Jun 4, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: